Breast cancer screening in America has been stuck at the same red light for decades. Every woman over 40, line up, get your annual mammogram, move along - no detours, no express lanes, no consideration for whether you're driving a moped or a semi-truck. Laura Esserman, Olufunmilayo Olopade, and Martin Eklund just fired back in JAMA at critics who questioned whether there's a better route, and their GPS is called the WISDOM trial.
What Exactly Are We Arguing About?
Here's the backstory. In late 2025, the WISDOM (Women Informed to Screen Depending on Measures of Risk) trial dropped its first major results in JAMA, and the breast cancer screening world collectively lost its mind. The trial took 28,372 women aged 40-74 and did something radical: instead of handing everyone the same annual mammogram ticket, researchers actually checked each woman's individual risk using genetic testing, polygenic risk scores, family history, and breast density. Then they sorted women into four lanes:
- Highest risk (~2%): Screening every 6 months, alternating mammography and MRI
- Elevated risk (~8%): Annual mammograms
- Average risk (~63%): Mammograms every two years
- Lowest risk (~26%): Hold off on screening until age 50
The result? Risk-based screening was just as safe as annual screening for catching dangerous cancers. In fact, the risk-based group had one-third fewer stage IIB+ cancers (30 vs. 48 per 100,000 person-years). Zero women in the highest-risk category - the ones getting the most intensive surveillance - developed advanced-stage cancer. Zero (Esserman et al., 2026).
The Criticism (Because There's Always a "Well, Actually...")
Frerik Smit and colleagues from the University of Fribourg and McGill raised a fair point in their letter to JAMA: what about overdiagnosis? That's the uncomfortable phenomenon where screening catches cancers that would never have caused trouble - tumors that would have just sat there, minding their own business, while doctors launched a full military operation against them. They questioned whether risk-based screening could truly reduce these harms (Smit et al., 2026).
It's a legitimate concern. Overdiagnosis is the screening debate's elephant in the room - the thing everyone knows is there but nobody can agree on the size of.
The Reply That Didn't Mince Words
Esserman, Olopade, and Eklund's response was essentially: "A one-size-fits-all approach to breast cancer screening is increasingly anachronistic." Which is academic-speak for "welcome to the 21st century, folks." Their argument boils down to this: breast cancer isn't one disease. It's a messy collection of different diseases hiding under one trench coat. Treating every woman's screening needs as identical ignores the massive variation in actual risk (Esserman et al., 2026).
And they've got receipts. The WISDOM trial didn't just theorize about personalization - it built a working model. Nine genes sequenced. Polygenic risk scores calculated. Clinical risk factors weighed. The result was a system that could tell a 45-year-old BRCA carrier apart from a 45-year-old with average breast density and no family history, then screen them accordingly.
Why This Actually Matters (Without the Hype)
Let's pump the brakes on calling this "groundbreaking" - that word has been applied to approximately 47,000 cancer studies that changed nothing. But here's what's genuinely interesting: 89% of women in the observational arm chose risk-based screening when given the option. That's not a marginal preference. That's a landslide.
And 30% of women found to carry cancer-risk genetic variants had no family history. Under current guidelines, many of these women wouldn't qualify for genetic testing at all. They'd be cruising along in the annual-mammogram lane, blissfully unaware they should be getting MRIs every six months.
The flip side? Risk-based screening didn't reduce biopsy rates, which was supposed to be a key win. More targeted screening was expected to mean fewer unnecessary biopsies, but the data didn't cooperate. That's the kind of honest result that builds trust - they didn't bury the finding that didn't go their way.
The Road Ahead
The WISDOM study is expanding into version 2.0, aiming to identify women at higher risk for aggressive cancers and offer personalized prevention - not just screening but actual intervention strategies. Meanwhile, AI tools like Clairity Breast are now showing up in NCCN guidelines, analyzing mammogram images to predict individual five-year breast cancer risk.
The screening wars aren't over. They probably won't be for years. But the era of identical screening for every woman regardless of her actual biology? That highway is closing, and the detour looks a lot smarter.
References
-
Esserman LJ, Fiscalini AS, Naeim A, Van't Veer LJ, et al. Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial. JAMA. 2026;335(9):763-774. doi:10.1001/jama.2025.24784. PMID: 41385349.
-
Esserman LJ, Olopade OI, Eklund M. Screening for Breast Cancer-Reply. JAMA. Published online April 6, 2026. doi:10.1001/jama.2026.1269. PMID: 41941225.
-
Smit F, Kaufman JS, Chiolero A. Screening for Breast Cancer. JAMA. Published online April 6, 2026. doi:10.1001/jama.2026.1266.
-
Defined Genomics Inc. Clairity Breast Added to NCCN Guidelines for Breast Cancer Screening and Diagnosis. OncLive. 2026.
-
Defined L, et al. A Systematic Review and Critical Assessment of Breast Cancer Risk Prediction Tools Incorporating a Polygenic Risk Score for the General Population. Cancers. 2023;15(22):5380. PMC10670420.
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.